Literature DB >> 28825917

Evaluation of an automatic MR-based gold fiducial marker localisation method for MR-only prostate radiotherapy.

Matteo Maspero1, Cornelis A T van den Berg, Frank Zijlstra, Gonda G Sikkes, Hans C J de Boer, Gert J Meijer, Linda G W Kerkmeijer, Max A Viergever, Jan J W Lagendijk, Peter R Seevinck.   

Abstract

An MR-only radiotherapy planning (RTP) workflow would reduce the cost, radiation exposure and uncertainties introduced by CT-MRI registrations. In the case of prostate treatment, one of the remaining challenges currently holding back the implementation of an RTP workflow is the MR-based localisation of intraprostatic gold fiducial markers (FMs), which is crucial for accurate patient positioning. Currently, MR-based FM localisation is clinically performed manually. This is sub-optimal, as manual interaction increases the workload. Attempts to perform automatic FM detection often rely on being able to detect signal voids induced by the FMs in magnitude images. However, signal voids may not always be sufficiently specific, hampering accurate and robust automatic FM localisation. Here, we present an approach that aims at automatic MR-based FM localisation. This method is based on template matching using a library of simulated complex-valued templates, and exploiting the behaviour of the complex MR signal in the vicinity of the FM. Clinical evaluation was performed on seventeen prostate cancer patients undergoing external beam radiotherapy treatment. Automatic MR-based FM localisation was compared to manual MR-based and semi-automatic CT-based localisation (the current gold standard) in terms of detection rate and the spatial accuracy and precision of localisation. The proposed method correctly detected all three FMs in 15/17 patients. The spatial accuracy (mean) and precision (STD) were 0.9 mm and 0.5 mm respectively, which is below the voxel size of [Formula: see text] mm3 and comparable to MR-based manual localisation. FM localisation failed (3/51 FMs) in the presence of bleeding or calcifications in the direct vicinity of the FM. The method was found to be spatially accurate and precise, which is essential for clinical use. To overcome any missed detection, we envision the use of the proposed method along with verification by an observer. This will result in a semi-automatic workflow facilitating the introduction of an MR-only workflow.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28825917     DOI: 10.1088/1361-6560/aa875f

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  5 in total

Review 1.  MRI-only treatment planning: benefits and challenges.

Authors:  Amir M Owrangi; Peter B Greer; Carri K Glide-Hurst
Journal:  Phys Med Biol       Date:  2018-02-26       Impact factor: 3.609

2.  Are cone beam CT image matching skills transferrable from planning CT to planning MRI for MR-only prostate radiotherapy?

Authors:  Rachel L Brooks; Hazel M McCallum; Rachel A Pearson; Karen Pilling; Jonathan Wyatt
Journal:  Br J Radiol       Date:  2021-04-29       Impact factor: 3.039

3.  Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy.

Authors:  Matteo Maspero; Peter R Seevinck; Nicole J W Willems; Gonda G Sikkes; Geja J de Kogel; Hans C J de Boer; Jochem R N van der Voort van Zyp; Cornelis A T van den Berg
Journal:  Radiat Oncol       Date:  2018-06-05       Impact factor: 3.481

4.  MR-PROTECT: Clinical feasibility of a prostate MRI-only radiotherapy treatment workflow and investigation of acceptance criteria.

Authors:  Emilia Persson; Christian Jamtheim Gustafsson; Petra Ambolt; Silke Engelholm; Sofie Ceberg; Sven Bäck; Lars E Olsson; Adalsteinn Gunnlaugsson
Journal:  Radiat Oncol       Date:  2020-04-09       Impact factor: 3.481

5.  Using C-Arm X-ray images from marker insertion to confirm the gold fiducial marker identification in an MRI-only prostate radiotherapy workflow.

Authors:  Christian Gustafsson; Emilia Persson; Adalsteinn Gunnlaugsson; Lars E Olsson
Journal:  J Appl Clin Med Phys       Date:  2018-10-24       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.